NGNE on Nasdaq
Neurogene Inc.
Pharmaceutical preparations company, listed on Nasdaq (NGNE)1
In its 2026 annual report the company says: “We are a clinical-stage biotechnology company committed to overcoming these limitations and turning today’s complex devastating neurological diseases into treatable conditions. We are building a robust and differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet need not otherwise addressable by conventional gene therapy.”3 It is headquartered in New York, New York.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Aeglea BioTherapeutics, Corbus Pharmaceuticals or Rallybio, or pick any stock.
- TickerNGNE on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersNew York, New York1
- Business address535 W 24Th Street, 5Th Floor, New York, Ny 100112
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake and expression. We are a clinical-stage biotechnology company committed to overcoming these limitations and turning today’s complex devastating neurological diseases into treatable conditions. We are building a robust and differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet need not otherwise addressable by conventional gene therapy. One approach we are taking harnesses our proprietary transgene regulation technology, EXACT TM (Expression Attenuation …3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue under licensing agreements | $0 | $925.0K |
| Research and development expenses | $75.0M | $60.9M |
| General and administrative expenses | $28.3M | $22.6M |
| Total operating expenses | $103.3M | $83.5M |
| Loss from operations | -$103.3M | -$82.6M |
| Interest income | $11.5M | $8.5M |
| Interest expense | -$5.0K | -$12.0K |
| Other income | $1.7M | $574.0K |
| Other expense | -$230.0K | -$1.6M |
| Net loss | -$90.4M | -$75.1M |
| Net loss per share, basic (in dollars per share) | -$4.24 | -$4.28 |
| Net loss per share, diluted (in dollars per share) | -$4.24 | -$4.28 |
| Weighted-average shares of common stock outstanding, basic (in shares) | 21.3M shares | 17.6M shares |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 21.3M shares | 17.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $103.8M | $136.6M | |
| Short-term investments | $165.2M | $175.8M | |
| Prepaid expenses and other current assets | $2.8M | $3.5M | |
| Total current assets | $271.8M | $315.9M | |
| Property and equipment, net | $12.8M | $15.4M | |
| Operating lease right-of-use assets | $2.6M | $3.0M | |
| Finance lease right-of-use assets | $22.0K | $71.0K | |
| Restricted cash | $339.0K | $339.0K | |
| Other non-current assets | $1.0M | $975.0K | |
| Total assets | $288.6M | $335.7M | |
| Accounts payable | $2.0M | $1.3M | |
| Accrued expenses and other current liabilities | $10.8M | $9.7M | |
| Operating lease liabilities, current | $3.0M | $2.9M | |
| Finance lease liabilities, current | $14.0K | $54.0K | |
| Contingent value rights liability, current | $638.0K | $1.1M | |
| Total current liabilities | $16.4M | $15.2M | |
| Operating lease liabilities, non-current | $6.8M | $9.4M | |
| Finance lease liabilities, non-current | $5.0K | $26.0K | |
| Contingent value rights liability, non-current | $428.0K | $718.0K | |
| Other liabilities | $51.0K | $51.0K | |
| Total liabilities | $23.7M | $25.4M | |
| Preferred stock, $0.000001 par value; 50,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.000001 par value; 450,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 15,489,800 and 14,854,725 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Additional paid-in capital | $617.5M | $572.7M | |
| Accumulated deficit | -$352.6M | -$262.3M | |
| Total stockholders' equity | $264.9M | $310.4M | $186.0M |
| Total liabilities and stockholders' equity | $288.6M | $335.7M | |
| Preferred stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | |
| Preferred Stock, shares, issued (in shares) | 0 shares | 0 shares | |
| Preferred Stock, shares, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 450.0M shares | 450.0M shares | |
| Common stock, shares, issued (in shares) | 15.5M shares | 14.9M shares | |
| Common stock, shares, outstanding (in shares) | 15.5M shares | 14.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $103.8M | $136.6M | |
| Short-term investments | $165.2M | $175.8M | |
| Prepaid expenses and other current assets | $2.8M | $3.5M | |
| Total current assets | $271.8M | $315.9M | |
| Property and equipment, net | $12.8M | $15.4M | |
| Operating lease right-of-use assets | $2.6M | $3.0M | |
| Finance lease right-of-use assets | $22.0K | $71.0K | |
| Restricted cash | $339.0K | $339.0K | |
| Other non-current assets | $1.0M | $975.0K | |
| Total assets | $288.6M | $335.7M | |
| Accounts payable | $2.0M | $1.3M | |
| Accrued expenses and other current liabilities | $10.8M | $9.7M | |
| Operating lease liabilities, current | $3.0M | $2.9M | |
| Finance lease liabilities, current | $14.0K | $54.0K | |
| Contingent value rights liability, current | $638.0K | $1.1M | |
| Total current liabilities | $16.4M | $15.2M | |
| Operating lease liabilities, non-current | $6.8M | $9.4M | |
| Finance lease liabilities, non-current | $5.0K | $26.0K | |
| Contingent value rights liability, non-current | $428.0K | $718.0K | |
| Other liabilities | $51.0K | $51.0K | |
| Total liabilities | $23.7M | $25.4M | |
| Preferred stock, $0.000001 par value; 50,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.000001 par value; 450,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 15,489,800 and 14,854,725 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Additional paid-in capital | $617.5M | $572.7M | |
| Accumulated deficit | -$352.6M | -$262.3M | |
| Total stockholders' equity | $264.9M | $310.4M | $186.0M |
| Total liabilities and stockholders' equity | $288.6M | $335.7M | |
| Preferred stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | |
| Preferred Stock, shares, issued (in shares) | 0 shares | 0 shares | |
| Preferred Stock, shares, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 450.0M shares | 450.0M shares | |
| Common stock, shares, issued (in shares) | 15.5M shares | 14.9M shares | |
| Common stock, shares, outstanding (in shares) | 15.5M shares | 14.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$90.4M | -$75.1M |
| Stock-based compensation expense | $14.2M | $8.3M |
| Depreciation and amortization of property and equipment | $3.0M | $3.2M |
| Asset impairment | $120.0K | $91.0K |
| Non-cash operating lease expense | $800.0K | $741.0K |
| Amortization of finance lease right-of-use assets | $49.0K | $52.0K |
| Amortization and accretion of premiums/discounts on held-to-maturity investments | -$4.5M | -$2.4M |
| Change in contingent value rights liability | -$743.0K | $522.0K |
| Gain on lease modification | -$6.0K | $0 |
| Prepaid expenses and other current assets | $952.0K | -$327.0K |
| Other assets | -$58.0K | -$211.0K |
| Accounts payable | $627.0K | -$77.0K |
| Accrued expenses and other liabilities | $1.7M | -$2.8M |
| Operating lease liabilities | -$2.9M | -$2.6M |
| Net cash used in operating activities | -$77.2M | -$70.6M |
| Purchases of property and equipment | -$1.2M | -$808.0K |
| Purchases of held-to-maturity investments | -$269.5M | -$198.5M |
| Proceeds from maturities of held-to-maturity investments | $284.7M | $74.0M |
| Net cash provided by (used in) investing activities | $14.0M | -$125.3M |
| Payment of deferred offering costs related to at-the-market sales agreement | -$241.0K | $0 |
| Proceeds from sale of common stock in at-the-market sales agreement, net of offering costs | $30.4M | $0 |
| Offering costs in connection with pre-closing financing | $0 | -$4.3M |
| Transaction costs related to reverse merger | $0 | -$2.9M |
| Proceeds from the issuance of common stock upon exercise of options | $266.0K | $1.7M |
| Proceeds from private financing, net of offering costs paid | $0 | $189.6M |
| Principal payments on finance leases | -$61.0K | -$52.0K |
| Proceeds from the issuance of common stock under Employee Stock Purchase Plan | $84.0K | $0 |
| Net cash provided by financing activities | $30.4M | $184.1M |
| Net decrease in cash, cash equivalents and restricted cash | -$32.7M | -$11.8M |
| Additions to operating lease right of use assets from new operating lease liabilities | $0 | $60.0K |
| Property and equipment included in accounts payable and accrued expenses | $76.0K | $726.0K |
| Additions to finance lease right of use assets from new finance lease liabilities | $0 | $25.0K |
| Offering costs related to private offering, included in accounts payable and accrued expenses | $0 | $90.0K |
| Cash paid for interest | $5.0K | $12.0K |
| Deferred offering costs reclassified to additional paid-in capital | $50.0K | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
Neurogene Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Neurogene Inc.
- Prudential Financial Filed SCHEDULE 13G on Neurogene Inc., latest Oct 7, 2026
- JENNISON ASSOCIATES LLC Filed SCHEDULE 13G on Neurogene Inc., latest Oct 6, 2026
- BALYASNY ASSET MANAGEMENT L.P. Filed SCHEDULE 13G on Neurogene Inc., latest Aug 14, 2026
- Redmile Group, LLC Filed SCHEDULE 13G/A on Neurogene Inc., latest Aug 14, 2026 (8 filings since Feb 14, 2022)
- Trails Edge Capital Partners, LP Filed SCHEDULE 13G/A on Neurogene Inc., latest Aug 14, 2026 (2 filings since Dec 15, 2025)
- EcoR1 Capital, LLC Filed SCHEDULE 13G/A on Neurogene Inc., latest Nov 14, 2025 (3 filings since Feb 14, 2022)
- BAKER BROS. ADVISORS LP Filed SCHEDULE 13G/A on Neurogene Inc., latest Aug 14, 2025 (6 filings since Jul 19, 2023)
- Commodore Capital LP Filed SCHEDULE 13G/A on Neurogene Inc., latest Aug 14, 2025 (2 filings since Dec 11, 2024)
- FMR LLC Filed SCHEDULE 13G/A on Neurogene Inc., latest May 12, 2025 (2 filings since Nov 12, 2024)
- BlackRock Filed SCHEDULE 13G/A on Neurogene Inc., latest Apr 23, 2025 (4 filings since Feb 3, 2022)
- Casdin Capital, LLC Filed SCHEDULE 13G/A on Neurogene Inc., latest Feb 14, 2025 (2 filings since Nov 8, 2024)
- GREAT POINT PARTNERS LLC Filed SCHEDULE 13G/A on Neurogene Inc., latest Feb 14, 2025 (4 filings since Dec 27, 2023)
- Neurogene Inc. New York, New York
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Neurogene Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $26.9M4 Dec 31, 2025 | $26.6M4 Dec 31, 2024 | +1.2% |
| Accumulated depreciation | $14.1M4 Dec 31, 2025 | $11.2M4 Dec 31, 2024 | +26.3% |
| Property and equipment, net | $12.8M4 Dec 31, 2025 | $15.4M4 Dec 31, 2024 | −17.1% |
| Finance-lease assets | $22.0K4 Dec 31, 2025 | $71.0K4 Dec 31, 2024 | −69.0% |
| Operating-lease assets (leased space) | $2.6M4 Dec 31, 2025 | $3.0M4 Dec 31, 2024 | −11.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $103.8M4 Dec 31, 2025 | $136.6M4 Dec 31, 2024 | −24.0% |
| Marketable securities, current | $165.2M4 Dec 31, 2025 | $175.8M4 Dec 31, 2024 | −6.1% |
Properties, in its own words
We currently lease two properties for our principal offices: an approximately 42,000 square foot manufacturing facility in Houston, Texas, and an approximately 6,000 square foot office space in New York, New York. The Houston manufacturing facility is used for our in-house manufacturing, warehouse and cold storage functions, and the lease expires on August 31, 2029. The New York office space is our corporate headquarters. In November 2025, we extended the lease by an additional 19 months at a reduced cost per square foot, which now expires on January 31, 2028. In addition, we have established a hybrid work-from-home policy for many of our employees. We believe these spaces to be sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms.
In addition to our principal offices, we also lease a combined 39,572 square feet of office and laboratory space in Seattle, Washington that was previously used by Neoleukin prior to the merger for laboratory, discovery, research and development and general and administrative purposes. We have entered into a sublease with an unrelated third party for 6,272 square feet of that space, which will terminate concurrently with the end of our lease for such space on September 30, 2026. We are actively looking for a subtenant for the remaining 33,300 square feet of combined laboratory and office space, which is subject to a lease that will terminate on June 30, 2029. Any net proceeds we receive from any sublease of these properties will be payable to the holders of CVRs issued in connection with the merger, after adjustment for certain costs.
Item 2 of the 10-K filed Mar 24, 2026.3
Leadership
Who has led Neurogene Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerRachel McMinn Dec 26, 2023 to now12
- Chief executive officerDavid Main Mar 6, 2014 to Aug 9, 201813
- PresidentChristine Mikail Cvijic Dec 26, 2023 to now14
- PresidentDavid Main Mar 6, 2014 to Aug 9, 201813
- Chief financial officerSean Michael Smith Aug 14, 2023 to Aug 14, 202315
- Chief financial officerChristine Mikail Cvijic Dec 26, 2023 to now14
- Chief financial officerRobert Ho Mar 16, 2020 to Feb 2, 202216
- Chief financial officerKamran Alam Mar 6, 2014 to Aug 9, 201817
- Chief operating officerLloyd Mackenzie Mar 13, 2018 to Aug 9, 201818
Board members and other officers (34)
- Chief Commercial OfficerChristina Shafer Apr 20, 2026 to now19
- Chief Medical OfficerJulie Jordan Jan 18, 2024 to now20
- Chief Scientific OfficerStuart Cobb Dec 26, 2023 to now21
- Principal Accounting OfficerSean Michael Smith Mar 3, 2022 to Feb 3, 202322
- Senior Vice PresidentCarl Walkey Feb 2, 2021 to Aug 4, 202223
- Chief Commercial OfficerAbigail Jenkins Jun 15, 2016 to Mar 13, 201824
- Chief Medical OfficerBarbara Troupin Oct 6, 2016 to Mar 13, 201825
- VP, HR and AdministrationShelley McCloskey Dec 23, 2015 to Aug 9, 201826
- VP Technical OperationsLloyd Mackenzie Mar 6, 2014 to Mar 10, 201727
- CMO; Senior VP Clinical Dev.Stephen B. Shrewsbury Mar 6, 2014 to Mar 14, 201628
- Board memberKeith Woods Feb 24, 2026 to now29
- Board memberChristine Mikail Cvijic May 8, 2026 to now30
- Board memberCory S. Freedland Dec 26, 2023 to now31
- Board memberRachel McMinn Dec 26, 2023 to now12
- Board memberRobert Baffi Dec 26, 2023 to now32
- Board memberRohan Palekar Mar 4, 2022 to now33
- Board memberErin Lavelle May 16, 2022 to Jun 9, 202334
- Board memberMartin Babler Sep 10, 2020 to Jun 9, 202335
- Board memberLewis T. Williams Aug 12, 2019 to May 13, 202136
- Board memberSarah B. Noonberg Aug 12, 2019 to now37
- Board memberMeta Cantey Boyd Aug 23, 2019 to Aug 23, 201938
- Board memberKelvin Neu Mar 27, 2017 to Mar 27, 201739
- Board memberFelix Baker May 9, 2017 to Dec 20, 202340
- Board memberJulian Baker May 9, 2017 to Dec 20, 202340
- Board memberL.p. 667 May 9, 2017 to Dec 20, 202340
- Board memberSean P. Nolan Feb 26, 2015 to May 7, 202041
- Board memberDaniel J. Levitt Mar 6, 2014 to May 16, 201842
- Board memberDavid Main Mar 6, 2014 to Aug 9, 201813
- Board memberElaine Jones V. Mar 6, 2014 to Mar 6, 201443
- Board memberGary Bridger Mar 6, 2014 to May 9, 201844
- Board memberRobert Pelzer Mar 6, 2014 to May 9, 201845
- Board memberTodd E. Simpson Mar 6, 2014 to Jun 9, 202346
- General counselDonna Cochener Mar 15, 2022 to Aug 4, 202247
- General counselHolly Vance Oct 20, 2020 to Aug 5, 202148
Former names
Timeline
- Aug 11, 20268-K Results of operations49
- Jul 2, 20268-K Entered a material agreement; Other events50
- Jun 29, 20268-K Regulation FD disclosure; Other events51
- Jun 8, 20268-K Regulation FD disclosure52
- Jun 4, 20268-K Shareholder vote53
- May 12, 20268-K Results of operations54
- Apr 20, 20268-K Executive or director change; Regulation FD disclosure55
- Mar 24, 20268-K Results of operations56
- Feb 26, 20268-K Regulation FD disclosure57
- Jan 12, 20268-K Regulation FD disclosure58
- Nov 13, 20258-K Results of operations59
- Nov 12, 20258-K Regulation FD disclosure60
- Dec 26, 2023New chief executive Rachel McMinn becomes CEO12
- Mar 6, 2014New chief executive David Main becomes CEO13
Calendar
Coming up
- Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.99) a share, on Nov 13, 2025.61
When it reported results
- Aug 11, 2026Reported quarterly or annual results49
- May 12, 2026Reported quarterly or annual results54
- Mar 24, 2026Reported quarterly or annual results56
- Nov 13, 2025Reported quarterly or annual results59
- Aug 11, 2025Reported quarterly or annual results62
- May 9, 2025Reported quarterly or annual results63
- Mar 24, 2025Reported quarterly or annual results64
- Nov 18, 2024Reported quarterly or annual results65
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
307 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 66 major events, 97 insider forms, 56 large holders, 68 other. The latest 20:
- Oct 7, 2026SCHEDULE 13G EDGAR
- Oct 6, 2026SCHEDULE 13G EDGAR
- Oct 2, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 11, 202610-Q EDGAR
- Aug 11, 20268-K EDGAR
- Jul 7, 20264 EDGAR
- Jul 2, 2026424B5 EDGAR
- Jul 2, 20264 EDGAR
- Jul 2, 20268-K EDGAR
- Jun 30, 2026424B5 EDGAR
- Jun 29, 20268-K EDGAR
- Jun 16, 20264/A EDGAR
- Jun 16, 20264/A EDGAR
- Jun 16, 20264/A EDGAR
- Jun 16, 20263/A EDGAR
- Jun 8, 20268-K EDGAR
- Jun 4, 20268-K EDGAR
The 307 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
25 open-market trades by officers, directors and large owners since October 2021: 6 buys and 19 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Cvijic Christine MikailPresident and CFO | Sale | 4,200 | $36.13 | $151.7K | Form 4 |
| Jul 6, 2026 | Cvijic Christine MikailPresident and CFO | Sale | 600 | $36.02 | $21.6K | Form 4 |
| Jul 2, 2026 | Cvijic Christine MikailPresident and CFO | Sale | 4,061 | $34.82 | $141.4K | Form 4 |
| Jul 1, 2026 | Cvijic Christine MikailPresident and CFO | Sale | 739 | $34.06 | $25.2K | Form 4 |
| May 6, 2026 | Cvijic Christine MikailPresident and CFO | Sale | 9,600 | $31.25 | $300.0K | Form 4 |
| Mar 26, 2026 | Jordan JulieChief Medical Officer | Sale | 828 | $21.89 | $18.1K | Form 4 |
| Mar 26, 2026 | McMinn RachelChief Executive Officer | Sale | 3,352 | $22.07 | $74.0K | Form 4 |
| Mar 26, 2026 | Cvijic Christine MikailPresident and CFO | Sale | 2,558 | $21.62 | $55.3K | Form 4 |
| Mar 13, 2026 | Cobb StuartChief Scientific Officer | Sale | 6,797 | $20.81 | $141.4K | Form 4 |
| Mar 13, 2026 | Cvijic Christine MikailPresident and CFO | Sale | 4,045 | $20.81 | $84.2K | Form 4 |
| Feb 27, 2026 | Cvijic Christine MikailPresident and CFO | Sale | 4,800 | $25.11 | $120.5K | Form 4 |
| May 14, 2025 | Cobb StuartChief Scientific Officer | Sale | 6,797 | $15.15 | $103.0K | Form 4 |
| Mar 13, 2025 | Cvijic Christine MikailPresident and CFO | Sale | 4,501 | $16.94 | $76.2K | Form 4 |
| Nov 26, 2024 | AKKARAJU SRINIVAS10% owner | Buy | 48,770 | $25.83 | $1.3M | Form 4 |
| Nov 22, 2024 | Cvijic Christine MikailPresident and CFO | Buy | 24,000 | $20.48 | $491.5K | Form 4 |
| Nov 22, 2024 | McMinn RachelChief Executive Officer | Buy | 47,500 | $20.40 | $969.0K | Form 4 |
| Aug 17, 2023 | Baker Brothers Life Sciences LPDirector | Buy | 166,942 | $0.69 | $115.2K | Form 4 |
| Aug 16, 2023 | Baker Brothers Life Sciences LPDirector | Buy | 229,600 | $0.68 | $156.1K | Form 4 |
| Aug 15, 2023 | Baker Brothers Life Sciences LPDirector | Buy | 1,888,800 | $0.63 | $1.2M | Form 4 |
| Aug 11, 2023 | Smith Sean MichaelInterim CFO, Prin Acct Off | Sale | 1,323 | $0.62 | $820 | Form 4 |
All 25 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Prudential FinancialSCHEDULE 13G, 1 filing Oct 7, 202666
- JENNISON ASSOCIATES LLCSCHEDULE 13G, 1 filing Oct 6, 202667
- BALYASNY ASSET MANAGEMENT L.P.SCHEDULE 13G, 1 filing Aug 14, 202668
- Redmile Group, LLCSCHEDULE 13G/A, 8 filings Feb 14, 2022 to Aug 14, 202669
- Trails Edge Capital Partners, LPSCHEDULE 13G/A, 2 filings Dec 15, 2025 to Aug 14, 202670
- EcoR1 Capital, LLCSCHEDULE 13G/A, 3 filings Feb 14, 2022 to Nov 14, 202571
- BAKER BROS. ADVISORS LPSCHEDULE 13G/A, 6 filings Jul 19, 2023 to Aug 14, 202572
- Commodore Capital LPSCHEDULE 13G/A, 2 filings Dec 11, 2024 to Aug 14, 202573
- FMR LLCSCHEDULE 13G/A, 2 filings Nov 12, 2024 to May 12, 202574
- BlackRockSCHEDULE 13G/A, 4 filings Feb 3, 2022 to Apr 23, 202575
- Casdin Capital, LLCSCHEDULE 13G/A, 2 filings Nov 8, 2024 to Feb 14, 202576
- GREAT POINT PARTNERS LLCSCHEDULE 13G/A, 4 filings Dec 27, 2023 to Feb 14, 202577
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 3 filings Feb 14, 2024 to Feb 14, 202578
- RTW INVESTMENTS, LPSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Feb 14, 202579
- Samsara BioCapital, L.P.SC 13G/A, 2 filings Feb 14, 2024 to Nov 27, 202480
- Cormorant Asset Management, LPSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202481
- Lynx1 Capital Management LPSC 13G/A, 2 filings Dec 30, 2022 to Feb 14, 202482
- Rachel McMinnSC 13D, 1 filing Dec 21, 202383
- PICTET ASSET MANAGEMENT SASC 13G, 2 filings Feb 10, 2022 to Feb 3, 202384
- MILLENNIUM MANAGEMENT LLCSC 13G/A, 4 filings Jul 7, 2022 to Jan 19, 202385
- Manzano Daniel Adriano SilvaSC 13G/A, 1 filing Feb 11, 202286
- Umut UlgeSC 13G/A, 1 filing Feb 11, 202287
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Rachel McMinn | $618.8K | $3.2M88 | |
| 2025 | Christine Mikail | 48 | $556.0K | $2.8M88 |
| 2025 | Julie Jordan | 54 | $496.8K | $1.5M88 |
| 2024 | Founder and Chief Executive Officer | $595.0K | $3.5M88 | |
| 2024 | President and Chief Financial Officer | $515.0K | $3.4M88 | |
| 2024 | Chief Medical Officer | $460.0K | $2.5M88 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Samsara Biocapital, LLC | 1,717,127 | $54.0M | 4.4% | No change |
| Casdin Capital, LLC | 1,545,361 | $48.6M | 2.4% | +125,000 |
| Redmile Group, LLC | 1,412,199 | $44.4M | 3.0% | −47,400 |
| Rtw Investments, LP | 1,362,456 | $42.8M | 0.4% | No change |
| EcoR1 Capital, LLC | 1,271,342 | $40.0M | 2.0% | No change |
| BlackRock, Inc. | 1,057,983 | $33.3M | 0.0% | +52,913 |
| Baker Bros. Advisors LP | 991,691 | $31.2M | 0.2% | No change |
| Balyasny Asset Management L.P. | 818,706 | $25.7M | 0.0% | +100,317 |
| Trails Edge Capital Partners, LP | 714,885 | $22.5M | 3.6% | −67,902 |
| Toronto Dominion Bank | 681,337 | $21.4M | 0.0% | No change |
| Vanguard Capital Management LLC | 536,525 | $16.9M | 0.0% | +21,798 |
| Jennison Associates LLC | 518,582 | $16.3M | 0.0% | −9,103 |
| Citadel Advisors LLC | 408,982 | $12.9M | 0.0% | +21,951 |
| Great Point Partners LLC | 352,180 | $11.1M | 2.6% | −147,820 |
| ArrowMark Colorado Holdings LLC | 342,453 | $10.8M | 0.4% | −182,343 |
| Fmr LLC | 295,561 | $9.3M | 0.0% | −87,086 |
| Geode Capital Management, LLC | 293,182 | $9.2M | 0.0% | +14,179 |
| State Street Corp | 224,322 | $7.1M | 0.0% | −88,683 |
| Franklin Resources Inc | 204,280 | $6.4M | 0.0% | New |
| Morgan Stanley | 191,724 | $6.0M | 0.0% | −93,515 |
| UBS Group AG | 171,289 | $5.4M | 0.0% | −14,390 |
| Blair William & Co/il | 146,905 | $4.6M | 0.0% | −21,313 |
| Driehaus Capital Management LLC | 143,528 | $4.5M | 0.0% | +110,763 |
| Point72 Asset Management, L.P. | 141,920 | $4.5M | 0.0% | New |
| Moore Capital Management, LP | 141,636 | $4.5M | 0.1% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Neurogene Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARNeurogene Inc.1
- CIK0001404644
- Employer ID (EIN)98-05425933
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address535 W 24Th Street, 5Th Floor, New York, NY 100111
- Phone(877) 237-50201
- Shares outstanding20,011,382 as of Aug 7, 202611
- Public float$146.0M as of Jun 30, 20253
- AuditorDeloitte & Touche LLP, Morristown, NJ PCAOB ID 34; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceJun 25, 20071
- Filings750 in all: 4 (232), 8-K (148), 3 (44), 10-Q (38), SC 13G/A (38), SC 13G (36), SC 13D/A (17), CORRESP (14)1
All 48 form types
S-8 (14), 424B5 (13), DEFA14A (13), SCHEDULE 13G/A (13), 10-K (12), DEF 14A (12), EFFECT (11), UPLOAD (10), 144 (8), S-3 (7), 4/A (6), 425 (6), ARS (5), D (5), SCHEDULE 13G (5), 8-K/A (4), SC 13D (4), 424B3 (3), 5 (3), S-4/A (3), 3/A (2), CT ORDER (2), PRE 14A (2), REGDEX (2), S-1 (2), SEC STAFF LETTER (2), 10-K/A (1), 10-Q/A (1), 424B4 (1), 8-A12B (1), CERTNAS (1), DRS (1), DRS/A (1), DRSLTR (1), NT 10-Q (1), POS AM (1), POS EX (1), REGDEX/A (1), S-1/A (1), S-4 (1)
- Latest filingsAnnual report (10-K) Mar 24, 2026
Quarterly report (10-Q) Aug 11, 2026
Proxy statement (DEF 14A) Apr 16, 2026
Latest 8-K (8-K) Aug 11, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, par value $0.000001 per share | NGNE | The Nasdaq Global Market |
From the cover page of the 10-K filed Mar 24, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Neurogene Inc. names in Item 1A of its 10-K filed Mar 24, 2026: 73 risks under these headings, as written.3
- Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
- We have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale, and our results may vary from quarter to quarter.
- We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts.
- We have incurred significant losses since inception, expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have no products for sale, have not generated any product revenue and may never generate product revenue or become profitable.
- Risks Related to Discovery, Development and Commercialization
- We are substantially dependent on the success of our most advanced product candidate, NGN-401, and our clinical trial of NGN-401 may not be successful.
- We face competition from entities that have developed or may develop programs for the diseases we plan to address with NGN-401 and other product candidates in development.
- NGN-401 is in clinical development and our preclinical programs are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of, or commercialize, our product candidates, or experience significant delays in doing so, our business will be materially harmed.
- We currently utilize adeno-associated virus serotype 9 (“AAV9”) capsid for delivery of therapeutic transgenes to deliver our product candidates, which may limit the safety, purity, and efficacy or potency of such product candidates.
- Participants in our clinical trials may experience undesirable side effects, which could cause delays or prevent regulatory approval of our product candidates, limit the commercial potential or create significant negative consequences to our development plans, even if such side effects are ultimately determined not to be attributable or possibly attributable to our product candidates.
- We intend to identify and develop novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential success of product candidate development.
- The disorders we seek to treat have low prevalence and it may be difficult to identify and enroll patients with these disorders. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
The other 62 risks
- We may not be successful in identifying and advancing a strategy to continue the development of NGN-101 for CLN5 Batten disease, and in the meantime, may incur additional costs as we continue the post-dosing phases of our clinical trial for NGN-101.
- Our programs are focused on the development of therapeutics for patients with neurological diseases, which is a rapidly evolving area of science, and the approach we are taking to discover and develop product candidates is novel and may never lead to approved or marketable products.
- If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of NGN-401 or any other product candidates may be delayed and, as a result, our stock price may decline.
- Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.
- Preliminary, “topline” or interim data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures.
- Our current or future clinical trials may reveal significant adverse events or undesirable side effects not seen in our preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of NGN-401 or any other product candidates or result in potential product liability claims.
- We may expend our limited resources to pursue a particular product candidate, such as NGN-401, and fail to capitalize on candidates that may be more profitable or for which there is a greater likelihood of success.
- Even if regulatory approval is obtained, any approved products resulting from NGN-401 or any other product candidate may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products.
- We have never commercialized a product candidate and may lack the necessary expertise, personnel and resources to successfully commercialize a product candidate on our own or together with suitable collaborators.
- We have never completed any late-stage clinical trials and may not be able to file an IND application or other applications for regulatory approval to commence additional clinical trials on the timelines we expect. Even if we are able to complete such trials, the FDA or comparable foreign regulatory authorities may not permit us to proceed or could suspend or terminate any such trial after it has been initiated.
- Risks Related to Manufacturing
- Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business.
- We and our contract manufacturers for AAV9 are subject to significant regulation with respect to manufacturing of our products. The third-party manufacturing facilities on which we rely, our in-house manufacturing facility, and any manufacturing facility that we may have in the future, may have limited capacity or fail to meet the applicable stringent regulatory requirements.
- We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.
- Delays in developing our manufacturing capabilities or failure to achieve operating efficiencies from such capabilities may require us to devote additional resources and management time to manufacturing operations for future product candidates and may delay our product development timelines.
- Any contamination or interruption in our manufacturing process, shortages of raw materials or failure of our suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.
- We may not be able to successfully manufacture our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing resulting approved products, if any.
- Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
- Risks Related to Our Reliance on Third Parties
- We currently rely, and intend in the future to rely, on third parties to conduct a significant portion of our preclinical studies and existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.
- Risks Related to Our Business and Operations
- In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth.
- We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
- Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
- Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CDMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- Our systems, or those of any of our CROs, CDMOs, manufacturers, other contractors, third party service providers or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.
- We are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation, injunctive restrictions on data processing and/or adverse publicity and could negatively affect our operating results and business.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
- Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
- We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.
- We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.
- We maintain our cash at financial institutions, at times in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments.
- Risks Related to Intellectual Property
- Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.
- We may not be successful in obtaining or maintaining necessary rights to product candidates through acquisitions and in-licenses.
- Certain of our current product candidates and research programs are licensed from or based upon licenses from a third party and are field limited to certain indications. If these license agreements are terminated or interpreted to narrow our rights, our ability to advance our current product candidates or develop new product candidates based on these technologies will be materially adversely affected.
- If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
- We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs, liability and diversion of resources, and prevent or delay us from commercializing potential products.
- We may be subject to claims that we have wrongfully hired an employee from a competitor or that employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
- Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.
- We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
- Some intellectual property that we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.
- Risks Related to Government Regulation
- The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, or if we determine that we are not willing or able to complete the regulatory approval process given the resources required to do so, we will not be able to commercialize, or will be delayed in commercializing, such product candidates, and our ability to generate revenue will be materially impaired.
- Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict the time and cost of obtaining regulatory approval, if received at all, for any product candidates we may develop.
- The FDA has recently required additional and in some cases more stringent clinical trial designs and clinical trial data for gene therapy product candidates, even where companies believed they had previously established alignment with the FDA on their trial designs. If the FDA were to change its position regarding elements of our clinical trial design or the clinical data required to support approval of our product candidates, we may face additional expenses or challenges in gaining approval of such products.
- Disruptions at the FDA and other governmental agencies and regulatory authorities could negatively affect the review of our regulatory submissions or impact our ability to access the public markets, which could negatively impact our business.
- We may not be able to meet requirements for the chemistry, manufacturing and control of our product candidates.
- We intend to deliver our product candidates via a drug delivery device that will have its own regulatory, development, supply and other risks.
- We have in the past and may in the future conduct clinical trials for our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.
- Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated.
- Even if we receive regulatory approval of NGN-401 or other product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
- We may face difficulties from healthcare legislative reform measures.
- Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
- Even if we are able to commercialize NGN-401 or other product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such products at competitive prices which would seriously harm our business.
- We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.
- Healthcare legislative, regulatory or policy reform measures may have a negative impact on our business and results of operations, and could prevent commercial success of our product candidates.
- Governments outside the United States may impose strict price controls, which may adversely affect our revenue, if any.
- While we have received Fast Track designation and Breakthrough Therapy designation for NGN-401 for the treatment of Rett syndrome and NGN-401 has been accepted into the FDA’s START Pilot Program and RMAT program and has received PRIME designation from the EMA, such designations may not lead to a faster development or regulatory review or approval process.
- We may seek certain additional designations for our product candidates, including Priority Review designations by the FDA, however, even if we receive such designations, there is no guarantee that they would lead to faster development or regulatory review timelines or increase the likelihood of marketing approval for such product candidate.
- We have received orphan drug designation for NGN-401 for the treatment of Rett syndrome and we may seek orphan drug designation for certain future product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.
- We have received Rare Pediatric Disease designation by the FDA for NGN-401 for the treatment of Rett syndrome. However, Rare Pediatric Disease designation for any of our product candidates does not guarantee that the BLA for the product will qualify for a priority review voucher upon approval, and it does not lead to a faster development or regulatory review process, or increase the likelihood that our product candidates will receive marketing approval.
- General Risk Factors
- Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.
- We may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and our product liability insurance may not cover all damages from such claims.
Legal proceedings
We may from time to time be named as a party to legal claims, actions and complaints, including matters involving employment, intellectual property or others. We are not presently a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARNeurogene Inc. filings on SEC EDGAR
- 2SEC EDGARNeurogene Inc. filings on SEC EDGAR
- 3
- 4SEC EDGARNeurogene Inc. 10-K for fiscal 2025
- 5SEC EDGARNeurogene Inc. 10-K for fiscal 2023
- 6SEC EDGARNeurogene Inc. 10-K for fiscal 2019
- 7SEC EDGARNeurogene Inc. 10-K for fiscal 2020
- 8SEC EDGARNeurogene Inc. 10-K for fiscal 2021
- 9SEC EDGARNeurogene Inc. 10-K for fiscal 2022
- 10SEC EDGARNeurogene Inc. 10-Q for fiscal 2026
- 11SEC EDGARNeurogene Inc. 10-Q for fiscal 2026
- 12
- 13SEC EDGARDavid Main, Chief executive officer
- 14SEC EDGARChristine Mikail Cvijic, President
- 15
- 16SEC EDGARRobert Ho, Chief financial officer
- 17SEC EDGARKamran Alam, Chief financial officer
- 18
- 19
- 20SEC EDGARJulie Jordan, Chief Medical Officer
- 21
- 22
- 23SEC EDGARCarl Walkey, Senior Vice President
- 24
- 25
- 26
- 27
- 28
- 29SEC EDGARKeith Woods, Board member
- 30
- 31SEC EDGARCory S. Freedland, Board member
- 32SEC EDGARRobert Baffi, Board member
- 33SEC EDGARRohan Palekar, Board member
- 34SEC EDGARErin Lavelle, Board member
- 35SEC EDGARMartin Babler, Board member
- 36SEC EDGARLewis T. Williams, Board member
- 37SEC EDGARSarah B. Noonberg, Board member
- 38SEC EDGARMeta Cantey Boyd, Board member
- 39SEC EDGARKelvin Neu, Board member
- 40SEC EDGARFelix Baker, Board member
- 41SEC EDGARSean P. Nolan, Board member
- 42SEC EDGARDaniel J. Levitt, Board member
- 43SEC EDGARElaine Jones V., Board member
- 44SEC EDGARGary Bridger, Board member
- 45SEC EDGARRobert Pelzer, Board member
- 46SEC EDGARTodd E. Simpson, Board member
- 47SEC EDGARDonna Cochener, General counsel
- 48SEC EDGARHolly Vance, General counsel
- 49SEC EDGARResults of operations
- 50
- 51
- 52SEC EDGARRegulation FD disclosure
- 53SEC EDGARShareholder vote
- 54SEC EDGARResults of operations
- 55
- 56SEC EDGARResults of operations
- 57SEC EDGARRegulation FD disclosure
- 58SEC EDGARRegulation FD disclosure
- 59SEC EDGARResults of operations
- 60SEC EDGARRegulation FD disclosure
- 61NasdaqNasdaq calendar
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87SEC EDGARUmut Ulge SC 13G/A on Neurogene Inc.
- 88